Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20108 in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20108 in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adebrelimab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; HS 20108 (Primary) ; SHR 7787 (Primary)
  • Indications Neuroendocrine carcinoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Proof of concept
  • Sponsors Hansoh BioMedical R&D Company

Most Recent Events

  • 02 Jun 2026 Protocol has been amended to include five new arms (Experimental: HS-20108 and Adebrelimab Ia&Ib, Experimental: HS-20108 and SHR-7787 Ia&Ib, Experimental: HS-20108 Adebrelimab and SHR-7787 Ia &Ib, Experimental: HS-20108 and Cisplatin/Carboplatin Ia&Ib and Experimental: HS-2010, Adebrelimab and Cisplatin/Carboplatin Ia&Ib) , it has changed from 4 to 9.
  • 02 Jun 2026 Planned End Date changed from 27 Nov 2027 to 28 Feb 2029.
  • 02 Jun 2026 Planned primary completion date changed from 28 Oct 2027 to 31 Aug 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top